Sponsors (4)
The bill funds multi-year research, data collection, and outreach to improve diagnosis, treatment options, and tracking of disparities in uterine fibroid care — especially for minority women — but requires new federal spending, adds administrative and privacy burdens, and may not by itself expand coverage or deliver quick clinical breakthroughs.
Women with uterine fibroids (especially those of reproductive age) will get increased federal research funding and coordinated NIH efforts that aim to accelerate development of better diagnostics and fertility-preserving treatments.
Women — and especially racial and ethnic minority women at higher risk — will receive expanded outreach and education that raises symptom awareness and encourages earlier diagnosis and care.
Medicaid/CHIP beneficiaries and state policymakers will benefit from improved federal data collection and a federal/state expenditure report, enabling better tracking of service use and more informed policy decisions about access and spending.
Taxpayers will fund the program (authorized and appropriated amounts across FY2026–2030, including a $30M/year research line and other unspecified "such sums"), increasing federal spending by tens to hundreds of millions over the period.
Greater awareness and research investments may not translate quickly into better care: clinical breakthroughs are uncertain and meaningful patient benefits could take years given the current limited evidence base.
Increased data collection, reporting, and program implementation will create additional administrative burdens and costs for states, Medicaid/CHIP programs, hospitals, and providers.
Based on analysis of 7 sections of legislative text.
Authorizes NIH‑coordinated fibroid research funding ($30M/yr FY2026–2030), creates Medicaid/CHIP data/reporting, and funds HHS education and clinician outreach.
Official title: Provide for research and education with respect to uterine fibroids, and for other purposes.
Introduced July 15, 2025 by Cory Anthony Booker · Last progress July 15, 2025
Expands federal research, data collection, education, and clinical outreach on uterine fibroids and funds those activities. It authorizes $30 million per year (FY2026–2030) for NIH-coordinated research, requires Medicaid/CHIP treatment data collection and a federal/state expenditure report, directs HHS to run public awareness and clinician outreach efforts (including promoting non‑hysterectomy options), and funds those activities through appropriations (some specified, some "as needed"). The law also defines “minority individuals” for the Act and emphasizes addressing racial disparities and gaps in evidence, diagnosis, and access to fertility‑preserving treatments for people affected by uterine fibroids.